RayBiotech and Gentel Partner to Offer Comprehensive Selection of Arrays on APiX Chromogenic Detection Platform
RayBiotech, Inc., a pioneer and leader in protein and antibody array technologies, and Gentel Biosciences, a leader in proteomics profiling tools, jointly announced today their partnership to develop and market RayBiotech's vast collection of easy-to-use antibody array products for use with Gentel's APiX™ chromogenic detection platform, a cost-effective alternative to laser fluoresecence scanners.
The new kits combine Gentel's APiX™ chromogenic detection technology and RayBiotech, Inc.'s collection of more than 55 antibody and protein arrays on a glass-slide format. Each kit is configured for use with the Gentel Proteomics Multi-System™ and Gentel's AthenaQuant® analysis software for an easy-to-use and cost-effective alternative to fluorescent-based detection. APiX chromogenic technology allows for the detection of any biotinylated molecule, generating light grey-to-black spots that are visible to the naked eye and can be scanned with the Gentel Proteomics Multi-System. The all-inclusive, "sample-into-data" workflow empowers both experts and novices with the necessary tools to conduct an experiment and obtain meaningful proteomics data in a single day.
"Raybiotech offers the most comprehensive selection of antibody and protein arrays on the market," says said Alex Vodenlich, Gentel's President and CEO. "Their collection of high-density, mid-density, and quantitative antibody arrays works seamlessly with their available ELISAs and antibody pairs to form a complete biomarker and proteomics workflow from hypothesis generation to validation. Integration with the Gentel Proteomics System and with Gentel's available arrays puts this complete proteomics workflow into a single box."
RayBiotech's glass-based array product line includes arrays targeting up to 500 proteins. These arrays have been featured in hundreds of publications, including research published in Nature (2008; 455; 391-395, Human PDGF-AA), Nature Medicine (2007; 13: 742-747, Mouse G-CSF), Proceedings of the National Academy of Sciences USA (2007; 104: 7438-7443, Mouse CXCL16, SDF-1), FASEB Journal (2009; 23: 351-361, Mouse SDF-1, SCF), and the Journal of Biological Chemistry (2007; 282: 34510-34524). The high quality arrays produced by RayBiotech, enable investigators in their biomedical research, biomarker and drug discovery and development.
Dr. Ray (Ruo-Pan) Huang, founder and President of RayBiotech, Inc. recognized the potential of the Gentel reagents and system for use with RayBiotech's Quantibody®, G-Series, and L-Series arrays. "Our customers are looking for a simple, sensitive, and affordable detection method for use with our array products. The Gentel Proteomics Multi-System and APiX detection meets this need," stated Dr. Huang. "We are excited about how RayBiotech's easy-to-use kits and Gentel's affordable system can help make arrays accessible to whole a new group of users."
These new APiX Antibody Arrays are available for purchase immediately from Gentel and are the third in a series of high-value products and services that Gentel is commercializing in the second half of 2010. As an introduction to the technology, Gentel will provide scanning and spot finding for a limited time free-of-charge using these kits. To learn more about the forty-nine new APiX Antibody Arrays, see how they augment your proteomics-research workflow and find out how to take advantage of the free "scan and report" service offer, please visit http://www.gentelbio.com/apixantibodyarrays.
About Gentel Biosciences, Inc.
Gentel delivers cost-effective, easy-to-use and reliable proteomics products and services that enable researchers to perform faster discovery, validation and screening of protein biomarkers to better understand disease and develop better therapies. Gentel's headquarters is located in Madison, Wisconsin.
About RayBiotech, Inc.
RayBiotech introduced the first commercially available cytokine antibody array in 2001. Since then, RayBiotech array products have been featured in hundreds of publications, including some in top-tier journals: Nature, Nature Medicine, Cell, Lancet, PNAS (USA), and many others. Offering more antibody array choices than any of its competitors, RayBiotech continues to lead in the development of protein array technologies. A spin-off from Emory University’s School of Medicine, RayBiotech is privately owned, with headquarters in metropolitan Atlanta (Norcross, GA).